Canada should invest in its research talent pipeline, says Canadian Institute For Advanced Research president
Stephen Toope, president of the Canadian Institute For Advanced Research, is a former vice-chancellor of Cambridge University and president of the University of British Columbia. He spoke to The Globe and Mail about the role of CIFAR, which brings people together from a range of disciplines to consider problems on the horizons of research, as a builder of scientific all-star teams.
Dr. Toope also discussed the state of research in Canada and the U.S., as President Donald Trump has slashed billions in research funds and attacked several of the most prominent American universities, including Harvard.
Q: What do you make of what has been happening between the U.S. government and Harvard?
A: It's appalling. And it's not just about Harvard. Billions of dollars of research funding have been removed, arbitrarily, from a whole range of different universities, always for slightly different reasons that don't meet the desires of the U.S. administration.
Q: You were invited to Ottawa for the Throne Speech. What are you hearing from the Government of Canada about its plans for research?
A: There was a brief mention of research and innovation, rather high level, which was 'to build Canada into the world's leading hub for science and innovation.' That's great. We've also seen the decision to have a minister for artificial intelligence, which suggests a comfort level with trying to deploy new technologies. The proof will be in the pudding.
Canada has some catch-up to play here. We have great strengths. We have a lot of solid and sometimes excellent universities. A lot of work needs to be done to make sure that our own ecosystem is strong and supporting research at an adequate level.
Q: What does CIFAR do?
We create networks of the very top people in the world who are interested in particular subjects. We bring them together across disciplines to try to unlock new approaches, new ideas, that are going to shape the future of research for decades to come. We're focused on some of the hardest questions facing science and humanity in the longer term.
We draw the people who are in CIFAR networks from the university world – you might think of them as the all-star team – to work on these really tough questions.
Q: How do you do manage an all-star team, and what are the challenges that come with it?
The first thing is to conceptualize where we should be expending our resources and what kinds of networks should we bring together. Looking at the horizon and trying to figure out what are the really difficult questions that CIFAR should be looking at now, because they're going to play out importantly in the world over the next 20 to 50 years. That's job one.
Job two is talent identification, making sure that we are well connected around the world, so that we know who's doing really exciting work and who has the impulse to work across disciplines collaboratively.
Q: Can the world make up for the money being pulled out of U.S. research?
No, that's a really important point to make. There's been some talk about how the universities will use some of their endowments, or the foundation world will step up. All of that money is a drop in the bucket, honestly, in relation to what has historically been the U.S. research endeavour.
Q: What should Canada be doing in response? What do you think is a wise way to invest?
I would start by analyzing where we are before we start inviting lots of new people into the system. Are we actually funding our research at the level that is necessary for a country with an advanced economy? I'm sad to say, I think the answer is no.
There was a modest bump up in research funding in the last federal budget of the previous government, but we're still really not operating at the same level of support that many other countries are. We've got to analyze where we should be making core investments to ensure that our whole ecosystem is strong. If we do that, we could then think about some targeted investment to bring in new talent.
If I were going to target the investment, I would say early- to mid-career researchers. I wouldn't be going after just two or three big names.
Q: Why do you say early-career is better than an established star?
Because you've got a longer runway if you can identify truly rising stars, and we've been good at that at CIFAR. If the government could think about a program designed to do that, then you've got people who are more likely to stay. If you invest in a person who's really very far advanced in their career, and then everything switches back with a new government in the U.S., it may be hard to hold on to those people.
Q: Tell me about this year's Azrieli scholars, whose names were announced last month?
This program is celebrating its 10th anniversary, and it's designed to identify really outstanding young researchers. What we're trying to do is wrap them around with support. So there's financial support to conduct their research, but more importantly there's skills support. How do you set up a lab effectively? How do you manage people? How do you establish priorities and stick with them?
We encourage them to be bold, to work across disciplines and to be really ambitious.
There are a number of published studies to indicate that despite all of the investment in science, we're actually getting results which are more and more incremental. We want to make sure that the next generation is encouraged to go for the breakthroughs. So we try to identify people from anywhere on the planet, and what they have in common is an aspiration to work across disciplines and a real, bold sensibility.
Q: How do you know what a 'bold sensibility' looks like?
It's usually around the ambition of the questions they're asking. One of the things CIFAR has been good at historically is pushing people to ask hard questions. Our very first program, 43 years ago, was artificial intelligence, robotics and society. That's pretty darn good in terms of foresight. We're trying to look for people who have that kind of questioning mind. They see an opportunity or challenge that other people haven't noticed yet.
This interview has been edited and condensed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
13 minutes ago
- CTV News
One Canadian on board as PM Carney says he's 'devastated' by the crash
One Canadian on board as PM Carney says he's 'devastated' by the crash CTVNews' Karmil Karamali on PM Mark Carney's reaction to the crash and the timeline leading up to the crash of the Boeing 787.

Globe and Mail
14 minutes ago
- Globe and Mail
Telus fails to deliver on Entwistle's IPO-based growth strategy
Would anyone buy another initial public offering promoted by long-serving Telus Corp. T-T chief executive officer Darren Entwistle? If the answer to that question is no, Mr. Entwistle's growth strategy at Telus is dead in the water. And it's hard to imagine investors stepping up for future Telus spinoffs after Tuesday's announcement that the parent company wants to put troubled offspring Telus International (Cda) Inc. TIXT-T out of its public market misery. Telus is offering to buy out shareholders in its subsidiary at a steep 86-per-cent discount to the price of its IPO, done with considerable fanfare just four years ago. Mr. Entwistle, a dominating personality who has been at the helm for 25 years, built Telus beyond its legacy phone networks by investing billions in subsidiaries focused on digital customer services, health care and agriculture. The idea was to incubate these businesses inside the Vancouver-based telecom, then launch them as public companies, with Telus shareholders reaping rewards from the value created on Mr. Entwistle's watch. Telus International – rebranded in 2024 as Telus Digital Experience – was meant to be the first in a series of spinoffs. Telus Health is up next, with an IPO anticipated as early as 2026. The incubator concept initially looked like a winner, as Telus Digital went public in 2021 at US$25 per share in what the parent company proudly heralded as the largest tech IPO in Toronto Stock Exchange history. At the time, Telus Digital's US$8.5-billion market capitalization rivalled that of the parent telecom. Execution failed to match ambition. Telus Digital proved a case study in value destruction. The company's challenges include a core business that runs call centres for clients such as retailers, hotels and banks. Artificial intelligence-based systems now dominate this space. Telus Digital proved slow to pivot, and customers moved on. On Wednesday, Telus reversed field by making a 'non-binding indication of interest,' or IOI, to acquire the 42.6 per cent of Telus Digital shares it doesn't own for US$3.40 each. Telus Digital shares promptly jumped 24 per cent Thursday to close at US$3.67 on expectations the parent company will be forced to goose its bid to get a deal done. Mr. Entwistle put a brave face on Telus Digital's face plant. In announcing the IOI, he said reintegrating the unit's tech expertise will benefit all of Telus's businesses, including telecom. While that may be true, buying back the subsidiary is an admission of failure. Telus set lofty goals for its diversification strategy, then failed to hit them. Telus proposes buying back Telus Digital for more than US$400-million Telus Health prepares to stand alone after years of acquisitions 'Today's rather dismal proposal has no 'congratulatory' terms that were to be found at the time of the IPO,' said analyst Tyler Tebbs at Tebbs Capital in a report. He said Telus is only offering to repurchase its subsidiary after failing to find a buyer for the business. Memories are long in financial circles. Mr. Tebbs compared the Telus offer to the ill-fated M&A at Time Warner Inc. in the recent past. He said the buyback 'is yet another example of a telecom/media company reversing a transaction done in much better times at the expense of shareholders.' In public markets, you're only as good as your last deal. Fund mangers got caught up in a craze for all things digital during the early days of the pandemic. That dynamic set the stage for a successful IPO at Telus Digital. The second time around, institutional and retail investors will be far more skeptical about buying when Mr. Entwistle is selling. To get an IPO done at Telus Health or Telus Agriculture, the parent company will likely be forced to accept a steep discount to the underlying value of the business, which defeats the purpose of the incubator concept. Yet without the ability to exit investments, Mr. Entwistle is running a debt-heavy conglomerate, anchored by a well-run but slow-growth telecom network that qualifies as critical infrastructure for the Canadian economy. Outside of founder-run businesses, it's hard to name a domestic public company more identified with its CEO than Telus. At Telus Digital, Mr. Entwistle's IPO-based growth strategy failed to deliver. The Telus board, chaired by former deputy prime minister John Manley, needs to ask hard questions about what comes next and who is best positioned to lead a business that has become the vision of a single executive.


Globe and Mail
14 minutes ago
- Globe and Mail
‘I forgot how tall I was': Former Humboldt Bronco Ryan Straschnitzki walks using exoskeleton
It's been a while since Ryan Straschnitzki looked at the world from a different perspective. The former Humboldt Broncos hockey player has been using a wheelchair since 2018, when he was paralyzed from the chest down in a bus crash in rural Saskatchewan that killed 16 people and injured 13 others. On Thursday, he demonstrated an exoskeleton that allowed him to walk along a 12-metre track in Calgary. 'I forgot how tall I was. I'm usually sitting really low, so I don't see people above their heads. Now being here, I get to see everybody's head. It's cool,' Straschnitzki said while standing in the wearable device. 'I feel like Iron Man in this thing. Just missing the helmet,' he added with a laugh. Vancouver-based Human in Motion Robotic's XoMotion system enables people with spinal cord injuries and in neurological rehabilitation to stand and walk with robotic support. Straschnitzki had been in the device before but got to control it Thursday. He used a small remote to move the device forward, backward and turn sideways. It also helped him handle a hockey stick and throw a football to staff at the rehab centre. 'It's pretty cool. I'm glad I played video games growing up,' he said. 'I got to learn how to two-step in this thing. Someone here's got to teach me, and I'll bring it to Stampede.' Straschnitzki said the technology wasn't even an option when he was injured. 'It was more so, is my body going to heal? Am I going to walk again on my own?' he said. 'Over time, you come to terms with the extent of your injuries. And then you realize that science is expanding every day, and there's technology like this one that will allow people with spinal cord injuries to walk again. It's super incredible and I'm very fortunate to try it.' The cost of the exoskeleton is about $400,000. Uyen Nguyen, executive director of Calgary's Synaptic Spinal Cord Injury and Neuro Rehabilitation Centre, said the exoskeleton mimics human motions. 'I never thought this was going to be possible. It's almost a Cinderella story that's come to life,' Nguyen said. 'It is one of the most advanced, because it is the most human-like in movement. Biomechanically, it is smooth. So when Ryan gets into it, it feels great, it feels natural.' The device will be offered to other patients at the centre, including those with spinal injuries or health problems like Parkinson's disease. Siamak Arzanpour, CEO of Human in Motion Robotics Inc., said the goal has always been to help those dealing with injuries have more independence. He said the long-term goal is to have exoskeletons deployed in real life activities, but there needs to be a controlled environment to prove they're safe first. He said Straschnitzki was the inspiration for developing the device. 'In 2018, Ryan probably didn't think about us. But from the beginning, we were thinking about him,' Arzanpour said. 'We wanted to use this device, helping him to walk again.'